Breo ellipta

Breo Ellipta is a bronchodilator used to treat lung diseases in the form of inhalation. The active ingredients in this medication are fluticasone, a corticosteroid, and vilanterol, a bronchodilator. These substances work to reduce inflammation and relax the respiratory muscles.

Breo Ellipta is sold as an inhalation powder and is produced by the pharmaceutical laboratory GlaxoSmithKline.

Indications of Breo Ellipta

Breo Ellipta is indicated for the treatment of maintenance of airway obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema. It is also indicated to reduce COPD exacerbations in patients with a history of exacerbations.

Directions for use of Breo Ellipta

The use of Breo Ellipta consists of an inhalation, once a day, exclusively orally. After inhalation, the patient should rinse his mouth with water, without swallowing to help reduce the risk of oropharyngeal candidiasis.

The Breo Ellipta must be taken at the same time every day. Do not use Breo Ellipta more than once every 24 hours.

Side Effects of Breo Ellipta

The most common side effects are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.

Contraindication for Breo Ellipta

Breo Ellipta is contraindicated in patients who are hypersensitive to milk proteins, or who have shown hypersensitivity to any component of the formula. It is not indicated for the treatment of asthma.